Ö

0031

RCE

CHIRINO, Arthur J.

1645

Please type a plus sign (+) inside this box $\rightarrow +$			TIO/SD/GA (00
Please type a plus sign (+) histor this box \rightarrow	. /	Approved for use through 10/31/2	2002. OMB 0651-
Under the Paperwork Reduction Act of 1995, no person. are required to resp	ond to a collection of information	n unless it contains a valid OMB c	ontrol number.
		Complete if Known	品
Substitute for form 1449A/PTO	Application Number	09/903,378	우
INFORMATION DISCLOSURE	Filing Date	July 10, 2001	Ω

First Named Inventor Group Art Unit

INFORMATION DISC STATEMENT BY APPLICANT

(use as many sheets as necessary)

Examiner Name A-69566-1/RFT/RMS/RMK Attorney Docket Number of 5 Sheet

Sheet	<u> </u>						2
					U.S. PATENT DOC	UMENTS	2/290
Examiner	Cite No.1	U.S. Patent			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant
Initials*	110.	Number	Kind Cod (if know	le² n)	of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear
MS	Al	6,269,312		Bl	MAYO et al.	07-31-2001	
	-						
	-					+	
	+	 					
	<u> </u>						
	<u> </u>	 					
	+						
	-	<u> </u>					
	+						
	+-						

		·			FOREIGN PATENT DOCUME	ENTS		
Examiner Initials*	Cite No.1	Foreig	gn Patent Docum	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
ms	B1	EP	0 752 886	B1	M&E BIOTECH A/S	01-1997		┷
/ //	B2	wo	98/52976	Al	BIOVATION LTD	11-1998		
	В3	wo	98/47089	Al	CALIF INST. TECHNOLOGY	10-1998		
- 	B4	wo	99/11777	A1	BIOVATION LTD	03-1999		
ners	В5	WO	00/34317	A3	BIOVATION LTD	06-2000		
		ļ						+
	-	 						

Examiner Signature	lefin	Date Considered	04/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) i	inside	this	box
-------------------------------	--------	------	-----

PTO/SB/8B (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no see any are required to respond	U.S. Patent and Trad	inless it contains a valid OMB control nu	ımber
74.0,40	ond to a conjection of information of	Complete if Known	- <u>후</u> _
Substitute for form 1449B/PTO	Application Number	09/903,378	0
INFORMATION DISCLOSURE	Filing Date	July 10, 2001	
STATEMENT BY APPLICANT	First Named Inventor	CHIRINO, Arthur J.	
STATEMENT DI ATTERCANT	Group Art Unit	1645	- 5
(use as many sheets as necessary)	Examiner Name		_ <u></u> 8_
	Attorney Docket Number	A-69566-1/RFT/RMS/RMK	
Sheet 2 0I 2 _			

Sheet	2	of 5 Attorney Docket Number A-69566-1/RF1/RIVIS/RIVIK	_	
Bileet			_	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ar				
mx	C1	ABRAMS, S.I. and SCHLOM, J., "Rational antigen modification as a strategy to upregulate or downregulate antigen recognition," <i>Curr Opin Immunol.</i> 2000 Feb;12(1):85-91		
	C2	ALTUVIA, Y. et al., "A structure-based algorithm to predict potential binding peptides to title molecules with	_	
	C3	ANDERTON, S.M. et al., "Therapeutic potential of TCR antagonists is determined by their ability to mediate a		
	C4	BOESTEANU, A. et al., "A molecular basis for how a single TCR interfaces multiple ligands, a minimum and the same and the	_	
	C5	BOWIE, J.U. et al., "A method to identify protein sequences that fold into a known three-uniterisional su detere."	_	
	C6	BRUSIC, V., et al., "MHCPEP, a database of MHC-binding peptides: update 1997," Nucleic Acids Res. 1996 3an	-	
	C7	BRUSIC, V., et al. "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural	L	
	C8	BUTTINELLI, G., et al., "Antigenic sites of poliovirus type 3 eliciting IgA monocional antibodics in orany	L	
	C9	BUUS, S. "Description and prediction of peptide-MHC binding: the numan NITIC project."	L	
	C10	1999 Apr;11(2):209-13 CHICZ, R.M. et al., "Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size," <i>Nature</i> . 1992 Aug 27;358(6389):764-8 molecules and are heterogeneous in size," <i>Nature</i> . 1992 Aug 27;358(6389):764-8	L	
	C11	CORREIA-NEVES, M. et al., "Amino acids specifying MHC class preference in Text v alpha 2 regions."		
	C12			
	C13	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
-	C14			
-	C15	Oct;4(10):2006-18 FLECKENSTEIN, B. et al., "New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 FLECKENSTEIN, B. et al., "New ligands binding to the human leukocyte antigen class II molecule DRB1*0101		
	C16	based on the activity pattern of an undecapeptide library," <i>Eur J Biochem.</i> 1996 Aug 15;240(1):71-7 FREMONT, D.H., et al. "Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb,"	T	
-	C17	Science. 1992 Aug 14;257(5072):919-27 GUILIKOTA K et al., "Two complementary methods for predicting peptides binding major histocompatibility	1	
	C18	complex molecules," J Mol Biol. 1997 Apr 18;267(5):1238-07	1	
nn	<u> </u>	peptide side chain scanning," J Exp Med. 1994 Dec 1;180(6):2353-8	_	

	pepude side chain seaming,			
Examiner Signature	Man	Date Considered	or for	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Please type a plus sign (+) inside this box _____

PTO/SB/8B (08-00)

Ε

Approved for use through 10/31/2002. OMB 0631-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF GOMMERC
U.S. Fatelit and Tratemark Office.

Jandha Dan	amunik Reduction Act of	1995 no	making are required to respo	nd to a collection of information	unless it contains a valid OMB contro	l aumb	er. <u>-</u>	7
			RADEMAN		Complete if Known	主	ا ا روست	
Substitute for form 1449B/PTO		Application Number	09/903,378	CE	ſΑ	 		
INE	ORMATIO	N DI	SCLOSURE	Filing Date	July 10, 2001	<u> </u>	ربر <u>دی</u>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	CHIRINO, Arthur J.	- 122	_ ල	
				Group Art Unit	1645	<u></u>	20	_
	(use as many sh	eets as	necessary)	Examiner Name		9	02	Л
Sheet	1 2	of	5	Attorney Docket Number	A-69566-1/RFT/RMS/RMK	987		工
SHEEL				<u> </u>		\sim		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
pm	C19	HAMMER, J. et al., "High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations." <i>Proc Natl Acad Sci U S A</i> . 1994 May 10;91(10):4456-60	+	
1	C20	HAMMER, J. "New methods to predict MHC-binding sequences within protein antigens." Curr Opin Immunot. 1995		
	C21	HAMMER, J. et al., "Rules governing peptide-class II MHC molecule interactions." <i>Behring Inst Mitt.</i> 1994	_	
	C22	HARBURY, P.B. et al., "Repacking protein cores with backbone freedom: structure prediction for coiled coils." <i>Proc</i>		
	C23	HELLINGA, H.W. and RICHARDS, F.M. "Optimal sequence selection in proteins of known structure by simulated analysis of Proc. Natl. Acad. Sci. U.S.A., 1994. Jun 21:91(13):5803-7	_	
	C24	HEMMER, B. et al., "Predictable TCR antigen recognition based on peptide scans leads to the identification of	_	
	C25	HIEMSTRA, H.S. et al., "Antigen arrays in T cell immunology." Curr Opin Immunol. 2000 Feb;12(1):80-4	_	
	C26	HOLLON, T., "Exposing Epitopes Without Exposing People," The Scientist 15(11):14, May 28, 2001	4	
	C27	HONEYMAN, M.C. et al., "Neural network-based prediction of candidate T-cell epitopes," <i>Nat Biotechnol</i> . 1998 Oct;16(10):966-9	_	
	C28	JONES, D.T. "De novo protein design using pairwise potentials and a genetic algorithm." <i>Protein Sci.</i> 1994 Apr;3(4):567-74		
	C29	KONO, H. and DOI, J. "Energy minimization method using automata network for sequence and side-chain		
	C30	LAM, K.S. et al., "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> . 1991 Nov 7;354(6348):82-4		
	C31	LAROCHE, Y. et al., "Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes," <i>Blood</i> . 2000 Aug 15;96(4):1425-32		
	C32	MADDEN, DR., "The three-dimensional structure of peptide-MHC complexes," Annu Rev Immunol. 1995;13:587-		
+-	C33	MALCHEREK, G. et al., "Analysis of allele-specific contact sites of natural HLA-DR17 ligands," J Immunol. 1994		
	C34	motife" I Comput Riol 1998 Winter 5(4):703-11		
	C35	MALLIOS, RR. "Class II MHC quantitative binding motifs derived from a large molecular database with a versatile	4	
ms	C36	F		

Examiner Signature	Wan	Date Considered	04/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

	4	0	TPE
.' Please type a plus sign (+)	inside this boy	MAR	2 2 2002
Please type a plus sign (+)	niside uns ook _	TO THE PARTY OF TH	

PTO/SB/RE (08-00)
Approved for use through 10/31/2002. OME 051-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	1 D 1	1005	To an in the comment	U.S. Patent and Trad	lemark Office: U.S. DEPARTMENT C unless it contains a valid OMB control	number	VE KE
			o persons a communato respe	ind to decine of an officered.	Complete if Known	Z	æ
Substit	tute for form 1449B/	PIO		Application Number	09/903,378	H	<u>र</u> ू
INF	ORMATIO	N DI	SCLOSURE	Filing Date	July 10, 2001	<u>ā</u>	<u>~</u>
			PPLICANT	First Named Inventor	CHIRINO, Arthur J.	_8	0
SIA)	III LICANI	Group Art Unit	1645	29	
	(use as many she	eets as	necessary)	Examiner Name		0	
Sheet	4	of	5	Attorney Docket Number	A-69566-1/RFT/RMS/RMK		

Examiner Cite No. 1		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
my	C37	MEISTER, G.E., et al., "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," <i>Vaccine</i> . 1995 Apr,13(6):581-91						
1	C38	MEYER, D.L. et al., "Reduced antibody response to streptavidin through site-directed mutagenesis," <i>Protein Sci.</i> 2001 Mar;10(3):491-503	\perp					
	C39	FRAZER, J.K. and CAPRA, J.D., "Immunoglobiulins: Structure and Function." in Fundamental Immunology Fourth Edition PAUL, W.E. (ed.), Lippincott-Rayen Publishers, Philadelphia, 1999, Chapter 3, pp. 37-74	_ _					
	C40	MARGULIES, D.H., "The Major Histocompatibility Complex," in Fundamental Immunology Fourth Edition, PAUL, W.F. (ed.) Lippincott-Rayen Publishers. Philadelphia, 1999, Chapter 8, pp. 263-285						
	C41	BENOIST, C. and MATHIS, D., "T-Lymphocyte Differentiation and Biology," in Fundamental Immunology Fourth Edition, PAUL, W.F. (ed.), Lippincott-Rayen Publishers, Philadelphia, 1999, Chapter 11, pp. 367-409						
	C42	PEREZ, M., "cDNA cloning and immunological characterization of the rye grass allergen Lol p I," J Biol Chem. 1990 Sep 25:265(27):16210-5						
1	C43	RAMMENSEE, H. et al., "SYFPEITHI: database for MHC ligands and peptide motifs," <i>Immunogenetics</i> . 1999 Nov;50(3-4):213-9						
-	C44	ROBERTS, C.G. et al., "Prediction of HIV peptide epitopes by a novel algorithm," AIDS Res Hum Retroviruses 1996 May 1;12(7):593-610						
	C45	RUDENSKY, A et al., "Sequence analysis of peptides bound to MHC class II molecules." <i>Nature</i> . 1991 Oct 17;353(6345):622-7						
	C46	SAROBE, P. et al., "Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions." <i>J Clin Invest.</i> 1998 Sep 15;102(6):1239-48						
	C47	SAVOIE, C.J. et al., "Use of BONSAI decision trees for the identification of potential MHC class I peptide epitope motifs." Pac Symp Biocomput. 1999;:182-9						
	C48	SCHWARTZ, H.L. et al., "High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase," <i>J Mol Biol.</i> 1999 Apr 16;287(5):983-99						
	C49	SETTE, A. et al., "Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II," <i>J Exp Med.</i> 1995 Feb 1;181(2):677-83						
	C50	SHASTRI, N., "Single T cell probes for antigen/MHC expression," Curr Opin Immunol. 1995 Apr,7(2):258-62						
1	C51	SHASTRI, N. "Needles in haystacks: identifying specific peptide antigens for T cells." <i>Curr Opin Immunol.</i> 1996 Apr;8(2):271-7						
	C52	SIDNEY, J. et al., "Measurement of MHC/Peptide Interactions by Gel Filtration," in Current Protocols in Immunology, Coligan, J.E. et al. (eds.), John Wiley and Sons (1998) 18.3.1-18.3.19						
m	C53							

Examiner Signature	Ums	Date Considered	04/03	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Please type a plus sigr	(+) inside this box	-> E
-------------------------	---------------------	------

PTO/SB/8B (08-00) Approved for use through 10/31/2002. OMB 065+6031

Under the Pat	perwork Reduction Act of	`1995. n	o person are required to respo	U.S. Patent and Trad	lemark Office: U.S. DEPARTMENT OF unless it contains a valid OMB control n	COMMERCE umber.
	tute for form 1449B		TRADEMAR		Complete if Known	<u> </u>
Suosa	tute for form 1447D	71 10		Application Number	09/903,378	
INF	ORMATIO	N D	ISCLOSURE	Filing Date	July 10, 2001	ER
STA	ATEMENT I	\mathbf{BY}	APPLICANT	First Named Inventor	CHIRINO, Arthur J.	16
~ 11				Group Art Unit	1645	00/
	(use as many sh	eets as	necessary)	Examiner Name		29(
Sheet	5	of	5	Attorney Docket Number	A-69566-1/RFT/RMS/RMK	8

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
my	C54	SINIGAGLIA, F. and HAMMER, J., "Motifs and supermotifs for MHC class II binding peptides," <i>J Exp Med.</i> 1995 Feb 1;181(2):449-51			
	C55	STURNIOLO, T. et al., "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nat Biotechnol</i> . 1999 Jun;17(6):555-61			
	C56	THIMME, R. et al., "Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51," <i>J Virol</i> . 2001 Apr;75(8):3984-7			
	C57	TSUTSUMI, Y. et al., "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity," <i>Proc Natl Acad Sci USA</i> . 2000 Jul 18;97(15):8548-53.			
	C58	UDAKA, K. et al., "Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries." <i>J Exp Med.</i> 1995 Jun 1;181(6):2097-108			
	C59	VOGT, A.B. and KROPSHOFER, H. "HLA-DM - an endosomal and lysosomal chaperone for the immune system." Trends Biochem Sci. 1999 Apr;24(4):150-4			
	C60	WALDEN, P. et al., "Elucidation of T-cell epitopes: a synthetic approach with random peptide libraries." <i>Biochem Soc Trans.</i> 1995 Aug;23(3):678-81			
	C61	WALDEN, P. "T-cell epitope determination." Curr Opin Immunol. 1996 Feb;8(1):68-74			
nus	C62	WATTS, C., "Capture and processing of exogenous antigens for presentation on MHC molecules," <i>Annu Rev Immunol</i> . 1997;15:821-50	-		
			+-		
			+		
	 		+		

Examiner Signature	lepin	Date Considered	04/03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.